(P024) Proton Radiotherapy for Midline CNS Lesions: A Class Solution

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

Midline and central lesions of the brain requiring conventional radiation therapy (RT) present complex difficulties in dose avoidance to organs at risk (OAR). In either the definitive or adjuvant setting, proper RT coverage of these lesions involves unnecessary treatment of large volumes of normal brain. We propose a class solution for these lesions using proton therapy (PrT).

Neil C. Estabrook, MD, Kevin P. McMullen, MD, Mark W. McDonald, MD, Hoene A. Ted, MS, CMD, Peter A. Johnstone, MD, FACR, Jeffrey C. Buchsbaum, MD, PhD, AM; IU Health Proton Therapy Center, Indiana University School of Medicine

Objective: Midline and central lesions of the brain requiring conventional radiation therapy (RT) present complex difficulties in dose avoidance to organs at risk (OAR). In either the definitive or adjuvant setting, proper RT coverage of these lesions involves unnecessary treatment of large volumes of normal brain. We propose a class solution for these lesions using proton therapy (PrT).

Materials and Methods: The records of the IU Health Proton Therapy Center were reviewed for patients presenting between January 1, 2009 and March 1, 2013 with midline central nervous system (CNS) lesions. Nine patients were identified. After institutional review board (IRB) approval was granted, their dosimetry was reviewed for target volume doses and OAR dose avoidance.

Results: Most of these cases were craniopharyngiomas (five cases); the others were meningiomas (four cases). In all nine cases, fields that were formed by the vertex and anterior and/or posterior superior oblique PrT beams along the midsagittal plane were used to provide coverage with minimal dose to the brainstem deep or to the cerebral hemispheres. The median prescribed dose using only midsagittal fields to target planning target volume (PTV) was 52.2 Gy relative biological effectiveness (RBE) (range: 48.6–61.2 Gy RBE), with a mean dose of 53.2 Gy RBE. The average of the mean doses to the brainstems using these fields in the nine plans was 18.0 Gy RBE (range: 0.0–40.1 Gy RBE). Similarly, the average of the mean doses to the hippocampi was 17.1 Gy RBE (range: 0.0–45.9 Gy RBE).

Conclusions: We consider these patients to be optimally treated with PrT and preferentially refer patients whenever possible. The use of modified midsagittal PrT schemas allows for treatment of midline CNS lesions with sparing of most of the uninvolved brain.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Related Content